Otros idiomas Foghorn Therapeutics Inc.

Acciones

FHTX

US3441741077

Diferido Nasdaq Otros sitios de cotización 15:33:13 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
5,47 ^USD	-4,54 %		+6,01 %	-15,19 %

09/04	Transcript : Foghorn Therapeutics Inc. - Special Call
07/03	Foghorn Therapeutics Inc. informa de los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Foghorn Therapeutics Names Kristian Humer CFO	16/04
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer	16/04
Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer	16/04
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs	09/04
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09/04
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference	05/04
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting	26/03
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook	07/03
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook	07/03
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909	05/03
Foghorn Therapeutics Inc. to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909	05/03
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference	28/02
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference	28/02
Eli Lilly : un antitumoral de Foghorn a été sélectionné	08/02
Foghorn Shares Rally as Eli Lilly Plans Clinical Program With Oncology Product	08/02
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor	08/02
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor	08/02
Foghorn Therapeutics Inc. Appoints Stephen J. Dipalma Interim Chief Financial Officer, Effective January 16, 2024	17/01
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024	08/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Foghorn Therapeutics Inc.

Acciones

FHTX

US3441741077

Otros idiomas

Filtros